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Abstract
On August 15, 2005, the Food and Drug Administration (FDA) and the As-
sociation of American Medical Colleges released a joint report that examines
possible steps to accelerate drug discovery and development. The report, enti-
tled Drug Development Science: Obstacles and Opportunities for Collaboration
Among Academia, Industry and Government, is the product of a two-day confer-
ence among leaders from the pharmaceutical industry, academia, and FDA. The
goal of the conference and the report was to explore means of overcoming the
high failure rate for tentative drug candidates.
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UNITED STATES
A High-Level Report on Accelerating 
Drug Discovery and Development 
in the United States
On August 15, 2005, the Food and Drug 
Administration (FDA) and the Association of 
American Medical Colleges released a joint 
report that examines possible steps to accelerate 
drug discovery and development. The report, 
entitled Drug Development Science: Obstacles and 
Opportunities for Collaboration Among Academia, 
Industry and Government, is the product of a 
two-day conference among leaders from the 
pharmaceutical industry, academia, and FDA. 
The goal of the conference and the report 
was to explore means of overcoming the high 
failure rate for tentative drug candidates.
The report explores issues relating to 
FDA’s Critical Path initiative, including:
• The challenges in translating biomedical 
knowledge and the rapidly growing 
number of potential disease targets into 
validated targets for drug discovery
• The importance of identifying and validating 
clinical biomarkers in both animal models 
and humans, and of validating biomarkers 
as surrogate end-points; and
• The need to reduce inefficiency in 
late phase clinical trials by use of new 
techniques and approaches to improve 
trial design and operations
The report concluded that there are several 
important opportunities to accelerate 
drug discovery and development. Among 
the major recommendations are that 
government, academia, and the pharmaceutical 
industry should work together to:
• Develop collaborative mechanisms 
to enable sharing of toxicology data 
across industry and the FDA
• Establish an inventory of validated biomarkers
• Create a consortium to analyze and 
learn from failed clinical trials
• Identify and propose to Congress new regulatory 
incentive policies for small market drugs
• Establish a public-private partnership to carry 
out whole genome association studies and 
deposit the data in the public domain
In the past year, FDA has encouraged an 
active dialogue with industry regarding ways 
to enhance the drug approval process, and 
this report describes an important set of 
policy questions and possible solutions.
FDA /AAMC Joint Report
EUROPE
EU Parliament Proposes Changes to EU 
Draft Regulation on Compulsory Licensing 
of Patented Pharmaceutical Products
On July 19, 2005, the EU Parliament published a 
report proposing changes to the EU Commission’s 
draft regulation on compulsory licensing. Following 
the WTO General Council Decision of August 
30, 2003, the draft regulation provides a two-
level procedure to lift EU patent protection of 
pharmaceuticals so that generics manufacturers 
can export them to developing countries. First, an 
eligible importing country (or, with such a country’s 
approval, a non-governmental organization or a 
United Nations body) has to notify the WTO (or, in 
case or a non-WTO member, the EU Commission) 
of its intention to use the system. Second, any 
person (e.g., generics producers) can then apply 
to the competent EU Member State authorities 
for a compulsory patent license to manufacture 
and export the pharmaceutical product in 
question. Except in emergency situations, the 
application can only be made if the applicant tried 
unsuccessfully for 30 days to obtain a negotiated 
license from the patent holder. The EU Parliament 
proposal would allow the Commission to establish 
criteria determining the level of remuneration 
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for the patent holder. Overall, it reflects a more 
favorable approach towards compulsory licensing 
by widening the scope of eligible importing 
countries (no longer limited to WTO members) 
and by relaxing the application-related procedural 
requirements. However, the draft regulation 
may still be modified by other EU institutions.
EU Parliament Report
Amended German Medicines 
Act Enters into Force
The 14th Amendment of the German Medicines 
Act entered into force at the end of August 
2005. This implements various EC Directives 
relating to human tissue quality and safety and 
herbal and human medicinal products, and 
amends the Cure Advertisement Act (HWG).
Unfortunately, the amended HWG does not provide 
the degree of liberalization of the drug advertisement 
market that had been expected. The provisions 
relating to the advertisement of non-prescription 
but prescribable drugs (for example, Antazida and 
H2 receptor blockers) have been expanded and the 
number of diseases for which drug advertisement 
outside expert circles (essentially, physicians and 
pharmacists) is forbidden has now been restricted 
to severe infectious diseases, malicious neoplasm, 
addiction diseases and illnesses connected to 
pregnancy and post-pregnancy. However, the 
permitted range of advertisement activities has 
not been significantly enlarged: the advertisement 
of ethical drugs, for example, remains excluded 
outside expert circles. In addition, effective as 
of April 1, 2006, misleading and/or suggestive 
advertising relating to plastic surgery is prohibited.
Medicines Act Amendment
INTELLECTUAL PROPERTY
UNITED STATES 
Supreme Court Broadens Infringement 
Safe Harbor for Drug R&D
In June, the Supreme Court issued an opinion in 
Merck v. Integra that has potentially enormous 
implications for pharmaceutical research and 
development. By more broadly interpreting a 
“safe harbor” from infringement, the Court may 
have effectively immunized a significant portion 
of drug research, at the expense of owners of 
patents relating to drug targets, lead compounds, 
discovery methods and, possibly, research tools. 
As a result, universities, biotech companies 
and big pharma may all wish to reassess their 
US patent strategies and research activities.
The Merck v. Integra case centered on a statutory 
exemption from infringement of a “patented 
invention . . . solely for uses reasonably related to 
the development and submission of information 
under a Federal law” regulating drugs. The Court 
of Appeals for the Federal Circuit had previously 
held that this exemption in the Hatch-Waxman Act 
was narrowly tailored and permitted “premarket 
approval activity conducted for the sole purposes 
of sales after patent expiration” (Hoechst-Roussel v. 
Lehman (1997)) in order to “facilitate the immediate 
entry of safe, generic drugs into the marketplace 
upon expiration of a pioneer drug patent” (Integra 
Lifesciences v. Merck (2003).) However, the Federal 
Circuit ruled that it did not “encompass drug 
development activities far beyond those necessary” 
for FDA approval; “globally embrace all experimental 
activity that at some point, however attenuated, 
may lead to an FDA approval process;” or “reach 
any exploratory research that may rationally form a 
predicate for future FDA clinical tests”. The Federal 
Circuit Court further warned that expansion of 
the exemption “to include [such] activities would 
effectively vitiate . . . biotechnology tool patents” 
and “swallow the whole benefit of . . . some 
categories of biotechnological inventions” (Integra). 
However, the Supreme Court disagreed—at 
least in part. Reversing the decision of the Federal 
Circuit, it held that the exemption “extends to all 
uses of patented inventions that are reasonably 
related to the development and submission of 
any information” to the FDA; that this “necessarily 
includes preclinical studies of patented compounds 
that are appropriate for submission to the FDA in 
the regulatory process;” and that there “is simply no 
room in the statute for excluding certain information 
from the exemption on the basis of the phase of 
research in which it is developed or the particular 
submission in which it could be included.” On the 
other hand, it held that “[b]asic scientific research 
on a particular compound, performed without the 
intent to develop a particular drug or a reasonable 
belief that the compound will cause the sort of 
physiological effect the researcher intends to induce” 
is not protected. Although the Court specifically 
declined to address research tool patents, it left the 
question open as to whether they were exempted.
While it is clear that the scope of the exemption 
has now been expanded—uses in preclinical 
investigations, uses that do not result in FDA 
submissions and uses unrelated to pre-expiration 
submissions for a generic drug may fall within 
it—its breadth remains unclear. Until further 
clarification is received from the Federal Circuit 
and, perhaps, the Supreme Court, owners of 
patents relating to drug targets, lead compounds, 
discovery methods and research tools may 
wish to reassess their US patent strategies and 
research activities, both in terms of the value of 
their patent rights and the risks of infringement.
Merck v. Integra (2005) 
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EUROPE 
UK Ratifies Revised European 
Patent Convention 
In July 2005, the UK became the fourteenth 
member state to ratify the amendments to 
the 1973 European Patent Convention (EPC), 
agreed by diplomatic conference in 2000.
The revised EPC aims to adapt ‘the existing 
1973 EPC to more effectively promote 
innovation and economic growth within Europe’, 
integrating developments in international patent 
law—in particular the TRIPS Agreement and 
the Patent Law Treaty. It is now expected 
to take effect not before late 2007.
The UK ensured compliance with the amended 
EPC provisions with the passing of the 2004 Patent 
Act in July 2004. A number of the key provisions 
of this Act entered into force on January 1, 2005. 
These impact upon remedies in entitlement 
proceedings, compensation of employees for certain 
inventions, threats of infringement proceedings, 
costs and expenses in infringement proceedings 
and enforcement of damages. A further set of 
provisions, including those relating to co-ownership, 
patent office opinions and security for costs, entered 
into force on October 1, 2005. The remaining 
provisions shall enter into force when the revised 
EPC takes effect, ensuring greater consistency 
and conformity with the practice of the EPO.
2000 EPC
Patents Act 2004
UK Patent Office Issues New Patentability 
Assessment Practice Notice 
In light of two recent judgments from the High 
Court, the Patent Office has issued a new Practice 
Notice advising of the approach its examiners shall 
now take to the examination of patentability. 
It advises that examiners should first look at the 
substance of the claim as a whole and identify the 
new and non-obvious advance in the art. They should 
then determine whether this advance is in fact new 
and obvious (and capable of industrial application), 
in light of the description of “invention” as set out in 
Article 52 of the EPC. Finally, they should consider 
whether the new and non-obvious element identified 
falls under the category of excluded matter, as 
set out in the 1977 Patents Act (as amended).
While the Office considered that the new 
approach should be applied with “immediate” 
effect, it does not materially affect the boundary 
of what is patentable. Each application shall 
continue to be assessed on its merits and account 
shall be taken of arguments put forward by the 
applicant. Furthermore, this approach remains 
subject to additional guidance by the courts. In 
the meantime, the clarification it offers and the 
attempt to harmonize with the approach of the 
European Patent Office (EPO) is welcomed.
In the Matter of CFPH LLC
Halliburton Energy Services v. Smith International
Patent Office Notice
ANTITRUST/COMPETITION
UNITED STATES
FTC Asks Supreme Court to 
Review Legality of Patent Settlement 
Agreements between Branded 
and Generic Manufacturers
On August 29, 2005, the Federal Trade Commission 
(FTC) filed a petition for writ of certiorari in the 
Supreme Court seeking review of an Eleventh Circuit 
Court of Appeals Decision against the FTC. As 
reported in the last issue, the Eleventh Circuit had 
reversed an FTC cease and desist order and had 
upheld the legality of two agreements settling patent 
infringement claims between branded manufacturer 
Schering-Plough and generic manufacturers 
Upsher-Smith and ESI Lederle, respectively.
The FTC seeks review on the question whether “an 
agreement between a pharmaceutical patent holder 
and a would-be generic competitor, in which the 
patent holder makes a substantial payment to the 
challenger for the purpose of delaying the challenger’s 
entry into the market, is an unreasonable restraint of 
trade.” The FTC also takes issue with the Eleventh 
Circuit’s application of the standard of review in 
rejecting the FTC’s earlier administrative conclusions.
In its petition, the FTC argues that the Eleventh 
Circuit mistakenly held that settlements “within the 
outer, nominal bounds of patent claims are presumed 
lawful.” The FTC urges that such a rule fails to take 
into account the substantial uncertainty in both the 
validity and reach of patents. Rather, the FTC believes 
that any substantial settlement payment from the 
patent holder to the generic manufacturer represents 
a “quid pro quo” for an “agreement by the generic 
to defer entry beyond the date that represents 
an otherwise reasonable litigation compromise,” 
reflecting the risk associated with that uncertainty.
The FTC relies heavily on its view that the Hatch-
Waxman Act signaled clear Congressional intent 
to foster generic entry and encourage challenges to 
blocking patents. That intent overrides, in its view, any 
public policy in favor of litigation settlement. It also 
cites empirical reports of successful generic challenges 
to such blocking patents, and of reduced consumer 
cost associated with increased use of generics.
The Supreme Court has full discretion whether 
to accept the matter for review. There is no set 
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timetable for that determination, but it could well 
occur in October or November of this year. If the 
petition is granted, additional briefing and argument 
would be considered before any ultimate decision.
FTC Petition
EUROPE
European Commission Fines 
AstraZeneca 60 Million Euros 
for Misuse of Patent System
On June 15, 2005, the European Commission 
fined Anglo-Swedish group AstraZeneca €60 
million for abusing its dominant position by: 
(1)  Giving misleading information to several 
national patent offices within the EEA in 
order to obtain supplementary protection 
certificates, giving extended patent 
protection for its ulcer drug, Losec; and 
(2)  (After AstraZeneca switched to a tablet 
version of Losec) Asking national agencies 
to de-register market authorizations for the 
capsule formulation of Losec, preventing generic 
producers from offering rival products.
The Commission concluded that these 
actions, which took place between 1993 and 
2000, made it almost impossible for other 
companies to launch competing generic 
products (keeping prices artificially high) and 
prevented parallel imports, and therefore 
amounted to an abuse of a dominant position. 
The Commission’s decision could signal a 
much stricter approach towards European 
pharmaceutical companies. While this type of 
conduct has in the past been found to violate US 
antitrust law, it is the first time the Commission 
has applied Article 82 EC Treaty in this way. 
Indeed, a Commission official confirmed that, 
because of the novelty of the situation, the “fine 
was lower than it would otherwise have been.”
AstraZeneca has appealed the Commission’s 
decision to the European Court of First Instance.
AstraZeneca Fined
OFT Launches a Review of NHS 
Procurement of Branded Pharmaceuticals
On September 13, 2005, the UK Office of Fair 
Trading launched a study into the Pharmaceutical 
Price Regulation Scheme (PPRS), the non-statutory 
scheme agreed between the Department of 
Health and industry to control the profit margins 
of manufacturers of branded pharmaceuticals, that 
have been licensed for prescribing on the NHS. 
The move comes only months after the PPRS was 
renewed until 2005. The study forms part of the 
OFT’s examination of public procurement in the UK. 
It is expected that the OFT will report on 
the findings of the study in Spring 2006. If 
the OFT concludes that the PPRS is in need 
of reform, it could recommend that the 
UK government change the PPRS, refer the 
PPRS to the Competition Commission for a 
fuller investigation, or take undertakings from 
pharmaceutical companies in lieu of a reference. 
OFT Review
 We would like to give special thanks for this 
edition to Corinne Atton, Christian Breuer, 
James Burling, Axel Desmedt, Jeffrey Francer, 
Christopher Hutton, Lars Klein, Andreas 
Seip, Peter Spaeth and Michael Twomey.
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